SIRT2 and Alzheimer disease: Another work demonstrated that inhibitor AK7 decreased the BACE1 and Aβ production in an AD mouse model, improving the cognitive functional defects of the mice; [86,119] one more study reported that AK7, via SIRT-2 inhibition, decreased the phosphorylated tau levels, a characteristic linked to tau pathology, resulting in increased Tau/tubulin and α-synuclein/tubulin binding, thus reducing tau and α-synuclein aggregation and neurotoxicity [120].